Month: March 2022

 – Well capitalized from $52 million IPO and $169 million in grant funding –– Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program –– Conference call and live audio webcast scheduled for Wednesday, March 30 at 8:00 a.m. ET – PURCHASE, N.Y., March 30, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today reported financial results for the year ended December 31, 2021 and provided recent business updates. “Our upsized initial public offering (IPO) in October 2021 supplemented...

Q4 Net Sales Increase of 16%; Q4 Comparable Sales Increase of 3.4% Q4 EPS increase of 13% to $2.49 Increases U.S. store potential to 3,500+ or triple current level Plans to double sales and more than double EPS through 2025 PHILADELPHIA, PA, March 30, 2022 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE) today announced financial results for the fourth quarter and full year of fiscal 2021 ended January 29, 2022, outlook for fiscal 2022 and its long-term vision at Investor Day 2022. Joel Anderson, President and CEO of Five Below, stated, “We were very pleased with our fourth quarter results that capped off a record year. We delivered sales growth in line with our expectations against the difficult comparison to last year’s stimulus-fueled comparable sales increase of 13.8%, and despite the impact of weather in January....

CHICAGO, March 30, 2022 (GLOBE NEWSWIRE) — Fast Radius, Inc. (“Fast Radius”) (Nasdaq: FSRD), a cloud manufacturing and digital supply chain company, reported financial results for the fourth quarter and full year ended December 31, 2021 for Fast Radius Operations, Inc. achieved prior to the completion of the business combination with ECP Environmental Growth Opportunities Corp. (“ECP”) in February 2022. Fourth Quarter 2021 Financial SummaryRevenue increased 52% to $6.4 million in 2021 compared to $4.2 million in 2020. Net loss was $22.9 million in 2021, or $5.33 per diluted share, compared to a net loss of $5.0 million, or $1.39 per diluted share, in 2020. Adjusted EBITDA loss was $17.5 million in 2021 compared to a loss of $4.5 million in 2020. Total Bookings were $7 million, an increase of 80% compared to 2020.Full...

Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023 Broad research platform presents opportunities for larger indications and partnerships; preclinical POC data in NOD2 Crohn’s disease expected by year end and IND filing planned in 2024 Plan to seek strategic alternatives for primary immunodeficiency programs, including OTL-103 in WAS Refined portfolio and 30% proposed workforce reduction extend cash runway into 2024 BOSTON and LONDON, March 30, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced its intention to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs...

Orgenesis to host conference call today at 12:00 PM ET GERMANTOWN, Md., March 30, 2022 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today reports its financial results for the year ended December 31, 2021 and provides a business update. Vered Caplan, CEO of Orgenesis, said, “Orgenesis’ revenues have increased more than four-fold to $35.5 million for 2021 compared to $7.7 million for 2020. In addition, we have already received commitments from customers for future revenues in excess of $30 million for 2022 and $55 million for 2023. The goal of our POCare Platform is to provide life-changing treatments to large numbers of patients through greater capacity and at reduced costs close to the hospital setting....

Fourth quarter revenue grew 41% while full year 2021 revenue grew 39%, exceeding Company’s outlookAnnual revenue surpasses €500 million for the first time in Company’s historyCompany projects solid annual revenue growth of 18% to 25% in fiscal 2022Secured multiyear partnerships with NHL, NBA, ITF, ICC, UEFA, Bundesliga ST. GALLEN, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or “the Company”), a leading global technology company enabling next generation engagement in sports, and the number one provider of business-to-business solutions to the global sports betting industry, today announced financial results for its fourth quarter and full year ended December 31, 2021. Full Year 2021 Highlights and Annual OutlookRevenue for the full year of 2021 increased 39% to €561.2 million...

Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. 2021 revenue of $31.3 million Sol-Gel to receive $21.5 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs based on a new agreement with Padagis; Sol-Gel to retain collaboration rights on two programs related to four high-value candidates Announced innovative pipeline which includes differentiated topical formulations of SGT-510 and SGT-310, which are expected to enter the clinic in 2022 Sol-Gel’s cash runway expected to extend through the end of 2023, assuming the timely approval of EPSOLAYNESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ:...